INmune Bio Inc. - Common stock (INMB) Social Stream
INMUNE BIO INC (INMB) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering INMUNE BIO INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 2 | $42 | $32 | $37 | $13.04 | 183.74% |
| 2022-01-24 | 2 | $42 | $20 | $31 | $13.04 | 137.73% |
| 2022-03-07 | 2 | $42 | $14 | $28 | $13.04 | 114.72% |
| 2022-05-11 | 2 | $22 | $14 | $18 | $13.04 | 38.04% |
| 2022-05-24 | 3 | $22 | $7 | $14.333 | $13.04 | 9.92% |
| 2022-12-16 | 2 | $22 | $7 | $14.333 | $13.04 | 9.92% |
| 2023-06-01 | 2 | $16 | $16 | $16 | $13.04 | 22.7% |
| 2023-10-20 | 2 | $22.001 | $16 | $19 | $13.04 | 45.71% |
| NA | 1 | $NA | $NA | $NA | $13.04 | NA% |
The Trend in the Analyst Price Target
INMB's average price target has moved down $13.75 over the prior 25 months.
Over the past 141 days, INMB's average upside potential has been 133.71%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-06-01 | 2 | 16.000 | 16 | 16 | 7.840 | 104.08% |
| 2023-06-01 | 1 | 16.000 | 16 | 16 | 7.840 | 104.08% |
| 2023-10-20 | 2 | 22.001 | 16 | 19 | 7.215 | 163.34% |
| 2023-10-20 | 3 | 22.001 | 16 | 19 | 7.215 | 163.34% |
INMB Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 2 | 0 | 0 | 0 | 0 | 2 |
The Trend in the Broker Recommendations
INMB's average broker recommendation rating improved by 1 over the prior 14 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for INMB as an investment opportunity.
- In terms of how INMUNE BIO INC fares relative to all US stocks, note that its number of analysts covering the stock is higher than 41.95% of that group.
- INMB has a lower variance in analysts' estimates than -534.28% of all US stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, INMUNE BIO INC's upside potential (average analyst target price relative to current price) is higher than 419.95% of them.
- INMUNE BIO INC's average analyst price target is greater than 434.6% of Healthcare stocks.
Stocks similar to INMUNE BIO INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are GMDA, GRTS, and AUTL.
View All Top Stocks by Price Target
Is INMB a Buy, Hold or Sell? See the POWR Ratings now!